HEART OUTCOMES PREVENTION EVALUATION (HOPE) - 3 - HEART OUTCOMES PREVENTION EVALUATION (HOPE) - 3

Population Health Research Institute (PHRI)0 个研究点目标入组 400 人开始时间: 待定最近更新: 2024年6月18日

适应症

试验速览

暂无简介。

•Women aged >60 with at least two additional CV risk factors and men > 55 with
•at least one additional CV risk factor:
•-Waist/hip ratio > 0.9 in men and > 0.85 in women
•-History of current or recent smoking (regular tobacco use within 5 years)
•-Low HDL cholesterol (<1 mmol/L in men and <1.3 mmol/L in women)
•-Dysglycemia
•-Renal dysfunction
•-Family history of premature CHD in first degree relatives;Provision of Informed Consent;Also see page 16 of the Study Protocol

•-Documented clinically manifest atherothrombotic CVD
•-Clear indication for statin and/or ARB or ACE inhibitor and/or thiazide diuretic therapy
•-Clear contra indication for statin and/or ARB or ACE inhibitor and/or thiazide diuretic therapy
•-Symptomatic hypotension
•-Other safety/contra-indications: i.e.: Chronic liver disease; inflammatory muscle disease; severe renal impairment; concurrent treatment with cyclosporine or a condition likely to result in organ tranplantation and the need for cyclosporine
•-concurrent treatment with a statin, fibrate, angiotensin receptor blocker, ACE nhibitor or a thiazide diuretic
•-Other serious medical illness likely to interfere with study participation or with the ability to complete the trial
•-mental disturbances, which could impair the ability to provide informed consent and to adhere to the trial procedures
•-concurrent us of an experimental pharmacological agent;Also see page 16 and 17 of the Study Protocol

发起方

Population Health Research Institute (PHRI)